ArticleMedical oncology (Northwood, London, England)2019

Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer.

Hisashi Tanaka et al.PubMed ↗Publisher ↗

No numbers read from the abstract.